Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 12/20 | 0.59 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264366 | 0.88 | SUCNR1 (0.69) | SUCNR1C3AR1KCNH2SCN10A | |
| SCHEMBL26263209 | 0.86 | SUCNR1 (0.61) | SUCNR1C3AR1 | |
| SCHEMBL26263219 | 0.85 | SUCNR1 (0.61) | SUCNR1C3AR1ICMT | |
| SCHEMBL26263232 | 0.85 | SUCNR1 (0.61) | SUCNR1C3AR1ICMT | |
| SCHEMBL26263201 | 0.84 | SUCNR1 (0.60) | SUCNR1C3AR1 | |
| SCHEMBL26263253 | 0.83 | SUCNR1 (0.83) | SUCNR1C3AR1ICMT | |
| SCHEMBL26263243 | 0.83 | SUCNR1 (0.68) | SUCNR1C3AR1ICMT | |
| SCHEMBL23091269 | 0.82 | KCNH2 (0.58) | SUCNR1C3AR1KCNH2SCN10A | |
| SCHEMBL26263245 | 0.81 | SUCNR1 (0.56) | SUCNR1 | |
| SCHEMBL26263255 | 0.80 | SUCNR1 (0.64) | SUCNR1C3AR1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885C3AR1 3636/4885KCNH2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.